CD133 expression in osteosarcoma and derivation of CD133+ cells

Li,Ji; Zhong,Xiao-Yan; Li,Zong-Yu; Cai,Jin‑Fang; Zou,Lin; Li,Jian‑Min; Yang,Tao; Liu,Wei

doi:10.3892/mmr.2012.1231

CD133 expression in osteosarcoma and derivation of CD133+ cells

Authors:
- Ji Li
- Xiao-Yan Zhong
- Zong-Yu Li
- Jin‑Fang Cai
- Lin Zou
- Jian‑Min Li
- Tao Yang
- Wei Liu
View Affiliations

Affiliations: Department of Orthopedics, The Fourth People's Hospital of Jinan/The Jinan Military General Hospital, Jinan 250031, P.R. China, Clinical Laboratory, The Eighth People's Hospital of Jinan, Jinan 250014, P.R. China, Department of Orthopedics, The Jinan Military General Hospital, Jinan 250031, P.R. China, Department of Orthopedics, Qilu Hospital Shandong University, Shandong 250012, P.R. China, Shandong Medical Association, Shandong 250014, P.R. China, Affiliated Hospital of Shandong Traditional Chinese Medicine University, Shandong 250012, P.R. China
Published online on: December 13, 2012 https://doi.org/10.3892/mmr.2012.1231
Pages: 577-584

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cluster of differentiation 133 (CD133) is recognized as a stem cell marker for normal and cancerous tissues. Using cell culture and real‑time fluorescent polymerase chain reaction, CD133 expression was analyzed in osteosarcoma tissue and Saos‑2 cell lines. In addition, cancer stem cell‑related gene expression in the Saos‑2 cell line was determined to explore the mechanisms underlying tumorigenesis and high drug resistance in osteosarcoma. CD133+ cells were found to be widely distributed in various types of osteosarcoma tissue. Following cell culture, cells entered the G2/M and S cell cycle stages from G0/G1. Levels of CD133+ cells decreased to normal levels rapidly over the course of cell culture. Colony forming efficiency was higher in the CD133+ compared with the CD133‑ subpopulation of Saos‑2 cells. Expression levels of stem cell‑related genes, including multidrug resistance protein 1 (MDR1) and sex determining region Y‑box 2 (Sox2) in the CD133+ subpopulation of cells were found to be significantly higher compared with the CD133‑ subpopulation. These observations indicate that CD133+ Saos‑2 cells exhibit stem cell characteristics, including low abundance, quiescence and a high potential to undergo differentiation, as well as expression of key stem cell regulatory and drug resistance genes, which may cause osteosarcoma and high drug resistance.

View Figures

View References

1	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
2	Huntly BJ and Gilliland DG: Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 5:311–321. 2005. View Article : Google Scholar : PubMed/NCBI
3	Marx J: Cancer research. Mutant stem cells may seed cancer. Science. 301:1308–1310. 2003. View Article : Google Scholar : PubMed/NCBI
4	Al-Hajj M, Wicha MS, Benito-Hernandez A, et al: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
5	Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
6	Goodell MA, Brose K, Paradis G, et al: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 183:1797–1806. 1996. View Article : Google Scholar : PubMed/NCBI
7	Meyers PA, Schwartz CL, Krailo M, et al: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin and high-dose methotrexate. J Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
8	Budak-Alpdogan T, Banerjee D and Bertino JR: Hematopoietic stem cell gene therapy with drug resistance genes: an update. Cancer Gene Ther. 12:849–863. 2005. View Article : Google Scholar : PubMed/NCBI
9	Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005. View Article : Google Scholar
10	Donnenberg VS and Donnenberg AD: Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol. 45:872–877. 2005. View Article : Google Scholar : PubMed/NCBI
11	Gerson SL: Drug resistance gene transfer: Stem cell protection and therapeutic efficacy. Exp Hematol. 28:1315–1324. 2000. View Article : Google Scholar : PubMed/NCBI
12	Richardson C and Bank A: Preselection of transduced murine hematopoietic stem cell populations leads to increased long-term stability and expression of the human multiple drug resistance gene. Blood. 86:2579–2589. 1995.PubMed/NCBI
13	Gibbs CP, Kukekov VG, Reith JD, et al: Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia. 7:967–976. 2005. View Article : Google Scholar : PubMed/NCBI
14	Yin AH, Miraglia S, Zanjani ED, et al: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 90:5002–5012. 1997.PubMed/NCBI
15	Lee A, Kessler JD, Read TA, et al: Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci. 8:723–729. 2005. View Article : Google Scholar : PubMed/NCBI
16	Sagrinati C, Netti GS, Mazzinghi B, et al: Isolation and characterization of multipotent progenitor cells from the Bowman’s capsule of adult human kidneys. J Am Soc Nephrol. 17:2443–2456. 2006.PubMed/NCBI
17	Richardson GD, Robson CN, Lang SH, et al: CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci. 117:3539–3545. 2004. View Article : Google Scholar : PubMed/NCBI
18	Kordes C, Sawitza I, Müller-Marbach A, et al: CD133⁺ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun. 352:410–417. 2007.
19	Sugiyama T, Rodriguez RT, McLean GW and Kim SK: Conserved markers of fetal pancreatic epithelium permit prospective isolation of islet progenitor cells by FACS. Proc Natl Acad Sci USA. 104:175–180. 2007. View Article : Google Scholar : PubMed/NCBI
20	Ito Y, Hamazaki TS, Ohnuma K, et al: Isolation of murine hair-inducing cells using the cell surface marker prominin-1/CD133. J Invest Dermatol. 127:1052–1060. 2007. View Article : Google Scholar : PubMed/NCBI
21	Collins AT, Berry PA, Hyde C, et al: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
22	Yin S, Li J, Hu C, et al: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 120:1444–1450. 2007. View Article : Google Scholar : PubMed/NCBI
23	Hermann PC, Huber SL, Herrler T, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007. View Article : Google Scholar : PubMed/NCBI
24	Eramo A, Lotti F, Sette G, et al: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15:504–514. 2008. View Article : Google Scholar : PubMed/NCBI
25	Kim CF, Jackson EL, Woolfenden AE, et al: Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 121:823–835. 2005. View Article : Google Scholar : PubMed/NCBI
26	Fang D, Nguyen TK, Leishear K, et al: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65:9328–9337. 2005. View Article : Google Scholar : PubMed/NCBI
27	Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon cancer initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
28	Prince ME, Sivanandan R, Kaczorowski A, et al: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 104:973–978. 2007. View Article : Google Scholar : PubMed/NCBI
29	Chambers I and Smith A: Self-renewal of teratocarcinoma and embryonic stem cells. Oncogene. 23:7150–7160. 2004. View Article : Google Scholar : PubMed/NCBI
30	Pan CX, Zhu W and Cheng L: Implications of cancer stem cells in the treatment of cancer. Future Oncol. 2:723–731. 2006. View Article : Google Scholar : PubMed/NCBI
31	Leslie EM, Deeley RG and Cole SP: Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2 and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 204:216–237. 2005. View Article : Google Scholar : PubMed/NCBI
32	Dietrich CG, Geier A and Oude Elferink RP: ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut. 52:1788–1795. 2003. View Article : Google Scholar : PubMed/NCBI
33	Staud F and Pavek P: Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol. 37:720–725. 2005. View Article : Google Scholar : PubMed/NCBI